Roughly 116,000 people with Medicare rely on the antipsychotic Vraylar to manage conditions that range from bipolar disorder to schizophrenia, and every one of them is about to see the government’s own price for that drug drop by nearly half. On January 1, the maximum fair price CMS negotiated for Vraylar takes effect, cutting the price from $1,376 to $770, a 44% reduction reached through the second cycle of Medicare’s drug price negotiation program.
The Math Behind a 44% Cut
CMS’s fact sheet on negotiated prices for 2027 lists Vraylar’s list price at $1,376 and its negotiated maximum fair price at $770, a difference of $606 the agency records as a 44% reduction. That percentage lands closer to the smaller end of the 15 cuts finalized in this cycle, which ranged from a 38% reduction on the smallest end to an 85% reduction on the largest, meaning Vraylar’s price still falls substantially even though several other drugs in the same round saw steeper proportional cuts. The new price takes hold on January 1, 2027, the same date set for every other drug CMS negotiated in this round. A $606 reduction on a single drug is smaller in dollar terms than some of the cuts on higher-priced cancer treatments in the same cycle, but it still represents a proportional drop of nearly half the original price, applied to a drug taken continuously by tens of thousands of people rather than a treatment used briefly and then stopped.
Inside the kit: 51 state Medicare cost-help packs, the new Part D out-of-pocket cap, the prior-authorization appeal steps and a medication and cost tracker sit together in one download, useful for lining up a psychiatric medication’s changing price against everything else a Part D plan already covers. Open The Medicare Cost & Coverage Protection Kit.
Bipolar Disorder, Depression and Schizophrenia: Vraylar’s Three Uses
Vraylar’s price qualifies it for negotiation because of how many conditions it treats and how many Medicare beneficiaries take it as a result. CMS’s companion selected-drug-list fact sheet lists bipolar disorder (the type-1 form), major depressive disorder and schizophrenia together as the drug’s Medicare-relevant uses, and records about $1.09 billion in Part D spending on it against roughly 116,000 beneficiaries. Covering three separate psychiatric diagnoses under one negotiated price is unusual among this cycle’s 15 drugs, most of which treat a single condition or a pair of closely related ones, and it is part of why Vraylar’s total spending figure sits close to the middle of the list despite its per-patient price being lower than some of the cancer and lung-disease drugs negotiated alongside it. Because the drug is approved for more than one diagnosis, a person could be prescribed Vraylar by a psychiatrist treating mood symptoms in one case and by a different specialist managing schizophrenia in another, and both prescriptions draw on the identical negotiated price once the new rate takes effect. That breadth of use is also why CMS’s spending total for the drug reflects such a wide range of patients rather than a single, narrowly defined diagnostic group.
Where Vraylar Sits in the Broader Negotiation Program
The authority to set Vraylar’s price at all traces back to the same law that produced every other negotiated price in this cycle. CMS’s own program overview page attributes the negotiation authority to the Inflation Reduction Act and states plainly that the maximum fair prices for this second cycle of 15 Part D drugs go into effect January 1, 2027. A first cycle of negotiated prices, covering an earlier set of drugs, already took effect in 2026, and CMS’s materials describe a third cycle of negotiations, with prices beginning in 2028, as already under way even as this round’s prices were being finalized. Vraylar’s new price is simply this cycle’s output for one specific drug within that larger, recurring statutory process. Each cycle runs on its own multi-year timeline: CMS selects the drugs, negotiates over a period of months with each manufacturer, and only then publishes the resulting maximum fair prices well ahead of the date they actually take effect, which is why the prices in this fact sheet were finalized well before the January 1, 2027 date that puts them into force.
What January 1 Changes for Someone Taking Vraylar
The negotiated price is a ceiling on what Medicare and a plan can be charged for the drug, not a direct rewrite of a patient’s own co-pay, which still depends on plan formulary tiers and cost-sharing rules that sit outside the negotiation itself. A prescription filled in December, before the new price applies, is billed under the current pricing structure, and the change to the lower price happens automatically on the effective date without requiring the patient to switch plans or take any action at the pharmacy. Because the psychiatric conditions Vraylar treats are typically managed with continuous, long-term medication rather than a short course, the $606 gap between the old and new price is one that recurs with each month’s refill for as long as the prescription continues, rather than a savings that applies just once. Over a full year of refills, that recurring $606 difference adds up to a far larger total than the single-month figures in CMS’s fact sheet suggest on their own, even before accounting for how a specific plan’s cost-sharing formula translates the lower price into an actual co-pay.
A Cheaper Antipsychotic and the Coverage Questions Around It
A 44% cut to one drug’s negotiated price does not settle whether a specific Part D plan places Vraylar on a favorable formulary tier or requires a prior authorization before covering it at all, and those separate plan rules can matter as much to a monthly bill as the underlying price does. Nothing about this price change touches the out-of-pocket cap that governs how high a person’s total annual drug spending can climb regardless of which drugs are on the list.
The Medicare Cost & Coverage Protection Kit pairs the prior-authorization appeal steps with the new Part D out-of-pocket cap that limits that annual total.
Look up the appeal steps in The Medicare Cost & Coverage Protection Kit.
This article was produced with AI assistance and reviewed by a human editor, drawing on CMS’s own negotiated-price and selected-drug fact sheets.
